Profile data is unavailable for this security.
About the company
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
- Revenue in USD (TTM)15.93m
- Net income in USD-64.59m
- Incorporated1971
- Employees189.00
- LocationVeru Inc2916 N. MIAMI AVENUE, SUITE 1000MIAMI 33127United StatesUSA
- Phone+1 (312) 595-9123
- Fax+1 (312) 595-9122
- Websitehttps://verupharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 208.20m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Renovaro Inc | 0.00 | -41.23m | 211.19m | 12.00 | -- | 2.29 | -- | -- | -0.685 | -0.685 | 0.00 | 0.6431 | 0.00 | -- | -- | 0.00 | -59.63 | -27.81 | -72.82 | -28.44 | -- | -- | -- | -- | -- | -22.12 | 0.1299 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 212.29m | 9.00 | -- | 1.95 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Lineage Cell Therapeutics Inc | 8.95m | -21.49m | 213.04m | 75.00 | -- | 3.12 | -- | 23.82 | -0.1243 | -0.1243 | 0.0518 | 0.3624 | 0.0796 | -- | 17.17 | 119,266.70 | -19.12 | -19.53 | -22.55 | -22.59 | 92.50 | 89.13 | -240.12 | -370.88 | -- | -- | 0.0023 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| G1 Therapeutics Inc | 82.51m | -47.97m | 215.58m | 100.00 | -- | 6.06 | -- | 2.61 | -0.953 | -0.953 | 1.53 | 0.6815 | 0.5332 | 0.5028 | 6.94 | 825,110.00 | -31.00 | -47.06 | -39.28 | -52.64 | 91.28 | -- | -58.13 | -268.59 | 3.45 | -5.22 | 0.593 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 216.02m | 32.00 | -- | 1.35 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Galectin Therapeutics Inc | 0.00 | -44.81m | 216.66m | 14.00 | -- | -- | -- | -- | -0.7456 | -0.7456 | 0.00 | -0.9739 | 0.00 | -- | -- | 0.00 | -165.97 | -92.08 | -394.92 | -121.97 | -- | -- | -- | -- | -- | -12.72 | 6.24 | -- | -- | -- | -15.26 | -- | -- | -- |
| Ovid Therapeutics Inc | 391.69k | -52.34m | 216.68m | 40.00 | -- | 2.46 | -- | 553.19 | -0.7415 | -0.7415 | 0.0056 | 1.24 | 0.0026 | -- | -- | 9,792.25 | -34.98 | -20.78 | -37.27 | -23.27 | -- | -- | -13,362.34 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Merrimack Pharmaceuticals Inc | 0.00 | -1.18m | 217.69m | -- | -- | 11.47 | -- | -- | -0.0826 | -0.0826 | 0.00 | 1.31 | 0.00 | -- | -- | -- | -6.05 | -23.52 | -6.22 | -26.08 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.51 | -- | -- | -- |
| Veru Inc | 15.93m | -64.59m | 218.11m | 189.00 | -- | 4.23 | -- | 13.69 | -0.758 | -0.758 | 0.177 | 0.3525 | 0.1728 | 1.01 | 5.10 | 84,285.19 | -70.07 | -42.91 | -101.20 | -54.41 | 50.31 | 72.41 | -405.44 | -104.96 | 2.79 | -- | 0.1584 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| Elevation Oncology Inc | 0.00 | -45.70m | 218.55m | 29.00 | -- | 3.10 | -- | -- | -1.53 | -1.53 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -49.88 | -- | -55.94 | -- | -- | -- | -- | -- | -- | -12.22 | 0.3548 | -- | -- | -- | 51.93 | -- | -- | -- |
| Codexis Inc | 70.14m | -76.24m | 219.43m | 174.00 | -- | 2.51 | -- | 3.13 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Boundless Bio Inc | 0.00 | -49.43m | 222.39m | 72.00 | -- | -- | -- | -- | -2.22 | -2.22 | 0.00 | 5.42 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 223.17m | 207.00 | -- | 4.53 | -- | 4.45 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.40 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| INmune Bio Inc | 155.00k | -30.01m | 229.23m | 11.00 | -- | 5.46 | -- | 1,478.89 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Veru Inc's reporting currency: US Dollar USD
34.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Adage Capital Management LPas of 31 Dec 2023 | 13.72m | 9.37% |
| Millennium Management LLCas of 18 Apr 2024 | 7.60m | 5.19% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 5.58m | 3.82% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.69m | 3.20% |
| Rosalind Advisors, Inc.as of 31 Mar 2024 | 4.50m | 3.07% |
| Octagon Capital Advisors LPas of 31 Dec 2023 | 3.80m | 2.60% |
| AIGH Capital Management LLCas of 31 Dec 2023 | 3.44m | 2.35% |
| AWM Investment Co., Inc.as of 31 Dec 2023 | 2.75m | 1.88% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.47m | 1.69% |
| Maven Investment Partners US Ltd. (US)as of 31 Dec 2023 | 2.39m | 1.63% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
